4basebio PLC (88Q.DE)
EUR 14.6
(0.0%)
EUR 14.6
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 340 Thousand GBP | 42.26% |
| 2022 | 239 Thousand GBP | -11.15% |
| 2021 | 269 Thousand GBP | -1.82% |
| 2020 | 274 Thousand GBP | 1078.57% |
| 2019 | -28 Thousand GBP | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -326.95 Thousand EUR | 0.0% |
| 2023 Q4 | -229.51 Thousand EUR | -16.02% |
| 2023 FY | 340 Thousand GBP | 42.26% |
| 2023 Q2 | -197.83 Thousand EUR | -250.92% |
| 2022 Q4 | 131.08 Thousand EUR | 229.73% |
| 2022 FY | 239 Thousand GBP | -11.15% |
| 2022 Q2 | -101.03 Thousand EUR | -506.83% |
| 2021 Q2 | 37.27 Thousand EUR | -76.83% |
| 2021 FY | 269 Thousand GBP | -1.82% |
| 2021 Q4 | -16.65 Thousand EUR | -144.67% |
| 2020 Q2 | 46.2 Thousand EUR | 0.0% |
| 2020 FY | 274 Thousand GBP | 1078.57% |
| 2020 Q4 | 160.87 Thousand EUR | 248.18% |
| 2019 FY | -28 Thousand GBP | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| BioNTech SE | 3.21 Billion EUR | 99.989% |
| CureVac N.V. | -70.6 Million EUR | 100.482% |
| Biotest Aktiengesellschaft | 271.9 Million EUR | 99.875% |
| Biotest Aktiengesellschaft | 271.9 Million EUR | 99.875% |
| BRAIN Biotech AG | 30.12 Million EUR | 98.871% |
| Formycon AG | 23.3 Million EUR | 98.541% |
| Heidelberg Pharma AG | 6.6 Million EUR | 94.853% |
| Medigene AG | 4.39 Million EUR | 92.257% |